A Phase 1 clinical trial reveals that a personalized mRNA vaccine, autogene cevumeran, combined with surgery and chemotherapy, shows promise in delaying pancreatic cancer recurrence.
A Phase II trial evaluating ESK981, a multi-tyrosine kinase inhibitor, combined with nivolumab in metastatic castration-resistant prostate cancer (mCRPC) was terminated due to futility.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.